(Q36600376)

15 August 2017

1 reference

title

The potential role of fowlpox virus in rational vaccine design (English)

1 reference

15 August 2017

1 reference

fowlpox virus

1 reference

Michael P Brown

2

0 references

John D. Hayball

object named as

John D Hayball

series ordinal

3

0 references

author name string

Emma L Beukema

series ordinal

1

1 reference

15 August 2017

1 August 2006

1 reference

Expert Review of Vaccines

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

565-577

1 reference

15 August 2017

4

1 reference

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

From Pasteur to genomics: progress and challenges in infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Modulating vaccine responses with dendritic cells and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The rational design of an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Immune response to poxvirus infections in various animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Genome of crocodilepox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Identification and characterization of three immunodominant structural proteins of fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The genome of fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Poxviruses and immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Recombinant fowlpox virus inducing protective immunity in non-avian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Reticuloendotheliosis Virus Sequences within the Genomes of Field Strains of Fowlpox Virus Display Variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Cellular receptors for viruses: links to tropism and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Poxvirus immunomodulatory strategies: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Target protease specificity of the viral serpin CrmA. Analysis of five caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The role of gamma interferon in antimicrobial immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

On immunity against infections and vaccines: credo 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The prime-boost strategy: exciting prospects for improved vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Virus-based vectors for human vaccine applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The Future of Smallpox Vaccination: is MVA the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Recombinant viruses as vaccines against viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Applications of pox virus vectors to vaccination: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Restriction endonuclease mapping of the fowlpox virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Progress toward an HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Induction of a strong HIV-specific CD8+ T cell response in mice using a fowlpox virus vector expressing an HIV-1 multi-CTL-epitope polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Vaccines with enhanced costimulation maintain high avidity memory CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Poxviruses as expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Fowlpox virus as a vector in non-avian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Crystal structure of a soluble CD28-Fab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Creation of killer poxvirus could have been predicted

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

An innately interesting decade of research in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Poxvirus-based vectors as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Cross-presentation, dendritic cells, tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Immunology. Nothing 'gainst time's scythe can make defense...

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Cross-presentation by intercellular peptide transfer through gap junctions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

On cross-priming of MHC class I-specific CTL: rule or exception?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Viral vectors for inducing CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Coupling and cross-presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.565

21 January 2018

Identifiers

DOI

10.1586/14760584.5.4.565

1 reference

15 August 2017

1 reference

PubMed ID

16989636